Spots Global Cancer Trial Database for Novel Peptide Vaccination for Patients With Advanced Bladder Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Novel Peptide Vaccination for Patients With Advanced Bladder Cancer

Official Title: Phase I Study of Vaccination With MPHOSHP1 and DEPDC1 Derived Epitope Peptides for HLA-A-24-positive Patients With Advanced Bladder Cancer

Study ID: NCT00635336

Conditions

Bladder Cancer

Interventions

MPHOSPH1 and DEPDC1

Study Description

Brief Summary: The purpose of this study is to evaluate the safety and clinical efficacy of novel vaccination for advanced bladder cancer.

Detailed Description: DEP domain containing 1(DEPDC1) and M phase phosphoprotein 1(MPHOSPH1) have been identified using genome-wide expression profile analysis by the use of cDNA microarray in our previous studies. We have determined the HLA-A\*2402 restricted epitope peptides derived from DEPDC1, DEPDC1-9-294, and MPHOSPH1, MPHOSPH1-9-278. These epitopes showed strong IFN-g production when stimulated with the appropriate targets expressed the appropriate protein and HLA-A\*2402. Furthermore, when vaccinated these peptides, specific CTLs were determined after the vaccination. Therefore we focused on the safety and efficacy of novel vaccination for the advanced bladder cancer patients who already showed resistance to standard chemotherapies or radiotherapy.